Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
1
33%
Ph phase_4
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)

Trials by Status

terminated133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_1

Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

NCT04322227
completedphase_4

Reduction in Pain Intensity Following IV or Oral Pain-relieving Products

NCT02678416
completedphase_2

Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches

NCT02472418

Clinical Trials (3)

Showing 3 of 3 trials
NCT04322227Phase 1

Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

Terminated
NCT02678416Phase 4

Reduction in Pain Intensity Following IV or Oral Pain-relieving Products

Completed
NCT02472418Phase 2

Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3